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Background: In the TRITON trial prasugrel 10 mg reduced ischemic events vs. clopidogrel 75 mg but increased bleeding, notably in patients with 
low body weight (LBW, <60 kg). Prasugrel 5 mg is recommended in LBW but pharmacodynamic (PD) data are limited. We performed a blinded, three-
period cross-over study in stable CAD patients weighing <60 kg (LBW) or ≥60 kg (HBW) examining PD with prasugrel (5 or 10 mg) and clopidogrel 
75 mg.
Methods: After a run-in on daily low dose aspirin, LBW subjects (n=34, 56.4 ± 3.7 kg) and HBW subjects (n=38, 84.7 ± 14.9 kg) were randomized 
to prasugrel (5 or 10 mg) or clopidogrel 75 mg during three 12-day periods. PD was measured with turbidimetric aggregometry (MPA to 20 μM ADP), 
VerifyNow P2Y12 (VN) and vasodilator-associated phosphoprotein (VASP) at pre-dose (baseline, BL) and at the end of each period.
Results: MPA to 20 μM ADP for prasugrel 5 mg in LBW subjects was similar to prasugrel 10 mg in HBW subjects (Figure). MPA was significantly 
lower for prasugrel 5 mg vs. clopidogrel 75 mg in LBW and for prasugrel 10 mg vs. clopidogrel 75 mg in HBW. Similar PD patterns were observed 
with VN and VASP. In LBW, higher rates of bleeding (mainly bruising) were seen with prasugrel 10 mg, while these were similar for prasugrel 5 mg vs. 
clopidogrel 75 mg. In HBW, bleeding rates were similar for all three treatments.
Conclusions: In aspirin-treated subjects with CAD, prasugrel 5 mg in LBW reduces platelet reactivity to a similar extent as prasugrel 10 mg in HBW, 
supporting the use of prasugrel 5 mg in LBW patients.
 
